Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /var/www/tarius.com/public_html/wp-content/plugins/revslider/includes/operations.class.php on line 2734

Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /var/www/tarius.com/public_html/wp-content/plugins/revslider/includes/operations.class.php on line 2738

Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /var/www/tarius.com/public_html/wp-content/plugins/revslider/includes/output.class.php on line 3679
Cardiovascular and Renal Drugs Advisory Committee – TARIUS – GLOBAL REGULATORY REQUIREMENTS
Loading Events

« All Events

Cardiovascular and Renal Drugs Advisory Committee

December 15

The committee will discuss supplemental new drug application (sNDA) 207620-S18, for the angiotensin receptor-neprilysin inhibitor, ENTRESTO (sacubitril and valsartan) tablets, submitted by Novartis Pharmaceuticals Corp., for the proposed indication of heart failure with preserved ejection fraction (HFpEF). Docket FDA-2020-N-1330.

Details

Date:
December 15
Event Category: